Lytix Biopharma to Take Lead Cancer Compound into Clinic
TROMS0, Norway--(BUSINESS WIRE)--The Scandinavian-based drug development company Lytix Biopharma announced its intention to take its lead anti-cancer molecule LTX-315 through to clinical trials. This decision follows the selection of Lytix’s first lead antimicrobial compound towards end of 2007.